Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microarray expression profiling of dysregulated mRNAs between ccRCC tumor tissues and corresponding adjacent normal tissues

ABSTRACT: Renal cell carcinoma (RCC) is the most common and lethal cancer of the adult kidney. Its incidence is increasing and outcomes remain poor. Accurate discrimination of RCC patients with poor prognosis was very important for the appropriate and effective patient management. ccRCC originated from dysregulation of different gene expression. To screen novel prognosis markers, a dysregulated mRNA expression profile was identified by microarray in some pairs of different stages ccRCC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE100666 | GEO | 2017/12/31

SECONDARY ACCESSION(S): PRJNA392456

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

LC-MS/MS proteomic profiling study of ccRCC cell-lines

Project description:We conducted comparative proteomic analysis with clear cell renal cell carcinoma (ccRCC), a subtype of RCC, have poorer prognosis and metastasize to the lungs, bones and lymph nodes. Comparative proteomic analysis in ccRCC study will reveals novel insights and development of disease.

2025-05-06 | PXD045898 | Pride

Microarray expression profiling of dysregulated long non-coding RNAs between RCC tumor tissues and corresponding adjacent tissues

Project description:During the past decade, increasing evidence has shown that lncRNAs play important roles in oncogenesis and tumor suppression; however, the roles of lncRNAs in RCC are poorly understood. To address this issue, we used Agilent human lncRNA microarray chips and bioinformatics tools to assess lncRNA expression in 5 pairs of RCC tissues. A dysregulated lncRNA expression profile was identified by microarray and verified by qRT-PCR in 60 pairs of renal cell carcinoma.

2017-06-10 | GSE88811 | GEO

Expression of PTTG1 is associated with aggressive clear cell renal carcinoma

Project description:The pituitary tumor-transforming gene (PTTG1) is a recently discovered oncogene implicated in the malignant progression of a number of neoplasms. It has been shown to drive both endocrine and non-endocrine malignancies, but has not yet been studied in the context of renal cell carcinoma (RCC). Clear cell RCC (ccRCC) is cytogenetically characterized by deletion of chromosome 3p, harboring the von-Hippel Lindau tumor suppressor gene, and amplification of chromosome 5q. The significance of copy number gain of chromosome 5 is not clear, but is presumed to be the location of oncogenes that influence ccRCC development or progression. The PTTG1 oncogene maps to chromosome 5q, and here we show that PTTG1 is amplified in clear cell RCC, is overexpressed in tumor tissue relative to adjacent normal kidney, and expression is associated with high grade, high stage, and poor prognosis. Furthermore, we establish a functional role for PTTG1 in ccRCC tumorigenesis and progression. PTTG1 ablation reduces both the tumorigenic ability of ccRCC cells in vitro and in vivo and the invasive ability of these cells in vitro. An analysis of genes whose transcription is regulated by PTTG1 was supportive of an association with invasive and metastatic disease. PTTG1-dependent expression of the Rho-GEF ECT2, another proto-oncogene, is observed in a number of ccRCC cell lines, and ECT2 expression correlates with PTTG1 expression, high stage, high grade, and poor prognosis ccRCC. As GEF's have been promoted as potential drug targets for targeted cancer therapeutics, the relationship between the PTTG1 and ECT2 oncogenes may be able to be exploited for the treatment of this disease. PTTG1 was knocked down by siRNA.

2013-07-31 | E-GEOD-25493 | biostudies-arrayexpress

CNV data from 133 ccRCC samples

Project description:Approximately 70% of clear cell renal cell carcinoma are characterised by the biallelic inactivation of VHL on chromosome 3p. ELOC-mutated renal cell carcinoma with biallelic ELOC inactivation on chromosome 8q are considered a novel subtype of renal cancer possessing a morphological overlap with ccRCC; however, the frequency and consequences of ELOC alterations in wtVHL and mutVHL is unclear. In this study, we characterise 123 renal tumours with clear cell morphology with known VHL mutation status to assess morphological and molecular consequences of ELOC inactivation. Using Oncoscan and whole exome sequencing we identify 18 ELOC deleted RCC, three of which contain ELOC mutations resulting in the biallelic inactivation of ELOC. Biallelic ELOC and biallelic VHL aberrations were mutually exclusive, although two ELOC-mutated RCC showed monoallelic VHL alterations. Using High Ambiguity Driven Biomolecular Docking we report a novel ELOC variant containing a duplication event disrupting ELOC-pVHL interaction alongside the frequently seen Y79C alteration. Using HRM mass spectrometry we show RCC with biallelic ELOC alterations have significantly reduced ELOC expression but similar CAIX and VEGFA expression when compared to classical ccRCC with VHL inactivation. These data demonstrate that RCC with ELOC and VHL alterations have comparable downstream effects with similar pathways to ccRCC tumourigenesis indicating that both entities are closely related.

2025-04-22 | GSE201277 | GEO

Effect of everolimus on clear cell renal cell carcinoma (ccRCC) cell lines - parental and stem cells

Project description:The aim of this study was to compare effect of everolimus on growth of different renal cell carcinoma (RCC) populations and develop design for experiments to measure the early response of everolimus in clear cell RCC (ccRCC) cell lines including renal cancer stem cells. Gene expression profiling using microarray was performed to determine the early response to everolimus after 3 days of treatment with optimizied concentration of drug in two ccRCC cell lines 1) parental clear cell renal cell carcinoma ccRCC-PCSC (HKPCSC -human parental kidney cancer stem cells) and 2) ccRCC-CSC - clear cell renal cell carcinoma -cancer stem cells (HKCSC - human kidney cancer stem cells).

2018-05-31 | GSE106819 | GEO

Expression data of A939572 SCD1 inhibitor treated ccRCC cells

Project description:Presently, there is a deficiency of effective therapies designed to target clear cell renal cell carcinoma (ccRCC), with poor prognosis resulting in patients with advanced disease. Additionally, there is a lack of molecular factors which can be remedially targeted resulting in tumor specific inhibition, and therefore current therapeutic approaches often produce adverse side effects in patients. We identified that Stearoyl-CoA desaturase 1 (SCD1) was consistently overexpressed in patient ccRCC samples, and further investigation of SCD1 as a potential molecular target for ccRCC intervention utilizing a SCD1 inhibitor (A939572) resulted in tumor specific growth inhibition and induction of cell death. In order to understand the mechanism by which the SCD1 inhibitor mediated its anti-tumor effects, we performed gene array analysis and compared expression patterns between treated and untreated samples. Four established ccRCC cell lines purchased from ATCC were treated with DMSO control versus A939572 over a 24 hour time period. RNA from each group was isolated and sent of for gene array anaylsis. Gene expression data from each individual treatment group was normalized to its respective DMSO contol, and resulting expression patterns associated with drug exposure was compared between the four cell lines.

2012-10-11 | E-GEOD-41485 | biostudies-arrayexpress

The m6A-mediated TGF-β-SMAD signaling axis regulates ccRCC progression [LACE-seq]

Project description:TGF-β-SMAD signaling pathway plays an important role in progression of various tumors. However, posttranscriptional regulation such as N6-methyladenosine (m6A) of TGF-β-SMAD signaling axis remains incompletely understood. Here, we reveal that Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) is low expression as well as associated with poor prognosis in clear cell renal cell carcinoma (ccRCC) patients and inhibits proliferation as well as promotes metastasis of ccRCC cells. To explore the underlying mechanism of IGF2BP2 in ccRCC, RNA-seq, RIP-seq and LACE-seq were performed to investigate the downstream targets of IGF2BP2.

2025-06-05 | GSE267275 | GEO

The m6A-mediated TGF-β-SMAD signaling axis regulates ccRCC progression [RIP-seq]

2025-06-05 | GSE267274 | GEO

The m6A-mediated TGF-β-SMAD signaling axis regulates ccRCC progression [RNA-seq]

2025-06-05 | GSE267273 | GEO

Identification of the novel progression factors in renal cell carcinoma through global proteomics

Project description:Renal cell carcinoma (RCC) is among the top 8 most diagnosed cancer in United States, which 79,000 patients newly were diagnosed and 13,920 deaths [1]. The clear-cell RCC (ccRCC) is the most common histopathological subtype representing approximately 85~90% in all diagnosed case [2]. In renal cancer treatment, metastasis is considered the most serious problem. Metastatic RCC (mRCC) is a fetal disease. It is known that about 25~30% of patients diagnosed with early kidney cancer have metastasized [3, 4]. The 5-year survival rate of patients with mRCC is 11.7%, and the prognosis is very poor [5]. Approximately 30% of patients have recurrence despite removal of the primary tumor, including 10-15% of patients found in T1 and clinically removed [4]. The mRCC patients show poor response to chemotherapy and radiotherapy, the rate of disappointing for treatment is increased from 15% to 25% [6, 7]. The common sites of RCC metastasis is known to the lung (40%), bone (30%), lymph node (22%) and liver (20%) [8].

2024-01-30 | PXD039207 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data